ReviewCardiovascular drugs and therapy2026
Targeting Systemic Immune Dysregulation in Cardiovascular Disease: From Mechanisms to Precision Therapeutic Strategies.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cardiovascular diseases remain a leading cause of morbidity and mortality despite advances in conventional pharmacological therapy. Persistent inflammation and immune dysregulation contribute to residual cardiovascular risk, disease heterogeneity, and variable therapeutic responses. Increasing evidence links cardiovascular injury to systemic immune and immunometabolic disturbances arising from the kidney, liver, brain, hematopoietic and lymphoid organs, gut, and adipose tissue. This review summarizes how systemic immune disturbances contribute to cardiovascular remodeling through altered immune-cell activation, impaired inflammatory resolution, metabolic stress, and pathological immune memory. We discuss the contributions of kidney-, liver-, neuroimmune-, gut-adipose-, and hematopoietic-associated abnormalities to major cardiovascular phenotypes, including heart failure with preserved ejection fraction, atherosclerotic cardiovascular disease, cardiorenal syndrome, metabolic cardiomyopathy, and aging-associated cardiovascular disease. These systemic abnormalities converge on common cardiovascular effector mechanisms, including endothelial dysfunction, inflammatory-cell recruitment, macrophage activation, fibroblast remodeling, extracellular matrix deposition, and cardiomyocyte dysfunction. We further examine emerging pharmacological strategies targeting systemic immune dysregulation, including cytokine inhibition, inflammasome modulation, metabolic interventions, and therapies targeting maladaptive immune memory. Although several approaches have demonstrated clinical benefit, effective translation requires identification of biologically defined patient subgroups, reliable biomarkers, and appropriate assessment of therapeutic response and safety. Integrating immune profiling with cardiovascular pharmacotherapy may facilitate a transition from nonspecific anti-inflammatory approaches toward precision modulation of pathological immune networks.
Indexed as
Identifiers
43009736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.